Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol effects on inflammation and calcification regulation in CKD stage 5D patients
2007-006606-16Phase 3Completed
- Sponsor
- University of Wuerzburg
- Start
- Jul 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of paricalcitol in chronic kidney disease (CKD), sponsored by University of Wuerzburg. Primary endpoints: Anti-inflammatory effect assessed by hsCRP, Calcification inhibitory effect assessed by fetuin-A and 2 more. Started Jul 2009; status: completed.
02
Drugs
paricalcitol
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2007-006606-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006606-16.